{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'submitted to the Sponsor for review and comment prior to submission for publication or', 'presentation. Trial patient identifiers will not be used in publication of results.', 'Authorship will be granted based on scientific input, recruitment efforts, and will be granted', 'upon decision of a publication committee. This committee will include among others the', 'Coordinating Investigator and the Sponsor.', 'The Sponsor will register and/or disclose the existence of and the results of clinical trials as', 'required by law.', '11.3.4.', 'Financing and Insurance', 'The Sponsor will fund the trial as outlined in the Clinical Trial Agreement.', 'The Sponsor will obtain adequate global/local insurance for the trial participants including', 'the trial patients for the required duration of time.', 'The Sponsor maintains an insurance coverage for this trial in accordance with the laws and', 'regulations of the countries in which the trial is performed. Liability and insurance provisions', \"for this trial are specified in the Investigator's contract. The terms and conditions will apply\", 'as specified in the policy document.', 'argenx BVBA', 'Confidential', 'Page 98 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '12.', 'REFERENCES', '1.', 'Barohn, R. J., Herbelin, L. (2000). \"The Quantitative Myasthenia Gravis Test Manual,', 'Myasthenia Gravis Foundation of America, Inc. Revised March 25, 2000. University', 'of', 'Texas, Southwestern Medical Center, Dallas, Texas.\",', 'from', 'http://myasthenia.org/LinkClick.aspx?fileticket=9U5kP6SfCJs%3D&tabid=125.', '2.', 'Barohn, R. J., D. McIntire, L. Herbelin, et al. (1998). \"Reliability testing of the', 'quantitative myasthenia gravis score.\" Ann N Y Acad Sci 841: 769-772.', '3.', 'Benatar, M., D. B. Sanders, T. M. Burns, et al. (2012). \"Recommendations for', \"myasthenia gravis clinical trials.' Muscle Nerve 45(6): 909-917.\", '4.', 'Burns, T. M., C. K. Grouse, M. R. Conaway, et al. (2010). \"Construct and concurrent', \"validation of the MG-QOL15 in the practice setting.' Muscle Nerve 41(2): 219-226.\", '5.', 'Burns, T. M., C.K. Grouse, G. I. Wolfe, et al. (2011). \"The MG-QOL15 for following', 'the health-related quality of life of patients with myasthenia gravis.\" Muscle Nerve', '43(1): 14-18.', '6.', 'Challa, D. K., U. Bussmeyer, T. Khan, et al. (2013). \"Autoantibody depletion', 'ameliorates disease in murine experimental autoimmune encephalomyelitis.\" MAbs', '5(5): 655-659.', '7.', 'Challa, D. K., R. Velmurugan, R. J. Ober, et al. (2014). \"FcRn: from molecular', 'interactions to regulation of IgG pharmacokinetics and functions.\" Curr Top Microbiol', 'Immunol 382: 249-272.', '8.', 'Drachman, D. B. (1994). \"Myasthenia gravis.\" N Engl J Med 330(25): 1797-1810.', '9.', 'EuroQoL.', '(2009).', '\"EQ-5D-5L.', 'Health', 'Questionnaire.', \"UK.'\", 'from', 'https://eurogol.org/wp-content/uploads/2016/10/Sample UK English EQ-5D-', '5L Paper Self complete v1.0 ID 24700.pdf.', '10.', 'Gilhus, N. E. (2016). \"Myasthenia Gravis.\" N Engl J Med 5(26): 2570-2581.', '11.', 'Gilhus, N. E. and J. J. Verschuuren (2015). \"Myasthenia gravis: subgroup classification', 'and therapeutic strategies.\" Lancet Neurol 14(10): 1023-1036.', '12.', 'Howard, J. F., Jr., R. J. Barohn, G. R. Cutter, et al. (2013). \"A randomized, double-', 'blind, placebo-controlled phase II study of eculizumab in patients with refractory', 'generalized myasthenia gravis.\" Muscle Nerve 48(1): 76-84.', '13.', 'Howard, J. F., Jr., K. Utsugisawa, M. Benatar, et al. (2017). \"Safety and efficacy of', 'eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised', 'myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-', 'controlled, multicentre study.\" Lancet Neurol 16(12): 976-986.', '14.', 'Kaminski, H. J. (2016). \"Seronegative Myasthenia Gravis-A Vanishing Disorder?\"', 'JAMA Neurol 73(9): 1055-1056.', '15.', 'Katzberg, H. D., C. Barnett, I. S. Merkies, et al. (2014). \"Minimal clinically important', \"difference in myasthenia gravis: outcomes from a randomized trial.' Muscle Nerve\", '49(5): 661-665.', '16.', 'Liu, J. F., W. X. Wang, J. Xue, et al. (2010). \"Comparing the autoantibody levels and', 'clinical efficacy of double filtration plasmapheresis, immunoadsorption, and', 'intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.\" Ther', 'Apher Dial 14(2): 153-160.', '17.', 'Meriggioli, M. N. and D. B. Sanders (2009). \"Autoimmune myasthenia gravis:', \"emerging clinical and biological heterogeneity.' Lancet Neurol 8(5): 475-490.\", 'argenx BVBA', 'Confidential', 'Page 99 of 110']\n\n###\n\n", "completion": "END"}